DLA Piper is providing legal counsel to Calliditas Therapeutics AB (Calliditas), a biopharmaceutical company based in Sweden, in relation to the recent tender offer made by Asahi Kasei Corporation (Asahi), a conglomerate from Japan. Asahi has offered to acquire all of Calliditas' outstanding shares and American Depositary Shares (ADSs) for a total of US$1.1 billion. […]
Calliditas Therapeutics AB (“Calliditas”) and Everest Medicines II Limited (“Everest”) announced that they have entered into a license agreement, in which Everest will develop and commercialize Calliditas’ leading drug candidate Nefecon in Greater China and Singapore for the chronic autoimmune kidney disease IgA Nephropathy (IgAN). Under the terms of the agreement, Calliditas will receive an […]
Lawyer Monthly is a news website and monthly legal publication with content that is entirely defined by the significant legal news from around the world.
We use cookies to ensure that we give you the best experience on our website. By continuing to use this site you consent to the use of cookies. Privacy PolicyOkI do not consent
